Announcement

Collapse
No announcement yet.

Pipeline Drugs from the MS Discovery Forum

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Pipeline Drugs from the MS Discovery Forum

    In recent news about disease-modifying drugs for relapsing-remitting MS, for example, dimethyl fumarate (Tecfidera/Biogen) may have a protective effect at the blood-brain barrier. Fingolimod (Gilenya/Novartis) appears to modulate T cell activation. Glatiramer acetate (Copaxone/Teva, Glatopa/generic) inhibits type I interferon signaling in monocytes. And this: Contrary to previous suspicions, cladribine (Movectro/Merck KGaA) may not be associated with an increased risk of cancer at doses used in MS trials.

    In managing symptoms, 5 years of postmarketing safety data for dalfampridine (Fampyra/Acorda), approved to improve walking in all forms of MS, have been published. And Synthetic Biologics ended its involvement in the development of estriol as an MS therapy after review of phase 2 trial results.

    These are just a few examples of the diverse bits of information captured in weekly updates to our drug database, a rich source of detailed information about key MS therapies. The complete rundown can be found here: http://www.msdiscovery.org/news/blog...pment-pipeline
Working...
X